Apimeds Pharmaceuticals US, Inc. (APUS) — Working Capital to Net Assets Ratio
Apimeds Pharmaceuticals US, Inc. (APUS) has a Working Capital to Net Assets ratio of 98.0% as of September 2025. Working capital of $8.00 Million (current assets of $9.09 Million minus current liabilities of $1.09 Million) is measured against net assets of $8.16 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See APUS equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Apimeds Pharmaceuticals US, Inc. Working Capital to Net Assets (2021–2024)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the ratio stands at 98.0%, reflecting working capital of $8.00 Million against net assets of $8.16 Million USD. Check APUS tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Apimeds Pharmaceuticals US, Inc. (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Apimeds Pharmaceuticals US, Inc. from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Apimeds Pharmaceuticals US, Inc. (APUS) market capitalisation.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 74.5% | $-1.01 Million | $-1.36 Million | $13.06K | $1.02 Million | ▼ -862.9 pp |
| 2023 | 937.4% | $298.76K | $31.87K | $422.08K | $123.31K | ▲ +893.5 pp |
| 2022 | 43.9% | $-313.61K | $-713.61K | $6.17K | $319.78K | ▲ +111.7 pp |
| 2021 | -67.7% | $161.52K | $-238.48K | $172.17K | $10.65K | — |